HeartSciences Named Among ‘50 Smartest Companies of the Year 2018’ by The Silicon Review Magazine
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180904005008/en/
MyoVista Wavelet ECG Cardiac Testing Device (Photo: Business Wire)
“The Silicon Review 50 Smartest Companies of the Year 2018 program identifies companies that mastered the discipline of smartness and stood high among the crowd,” said Sreshtha Banerjee, Editor-in-Chief of The Silicon Review Magazine.
“We are honored to be recognized by The Silicon Review Magazine as the one of the 50 Smartest Companies of 2018,” said Mark Hilz, CEO at HeartSciences. “HeartSciences use of patented signal processing methods combined with artificial intelligence is designed to bridge today’s “diagnostic gap” in cardiac care by providing low-cost effective solutions that help to identify cardiac dysfunction in the diastolic phase.”
HeartSciences is advancing the field of electrocardiography through the application of Wavelet Signal Processing and Artificial Intelligence to develop next generation ECG technology. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista wavECG Cardiac Testing Device is a 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to the proprietary informatics, the MyoVista wavECG device also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training as well as easy and intuitive use. The MyoVista wavECG device is not currently approved for sale or distribution in the United States and is not currently FDA cleared.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit: www.heartsciences.com
The following link leads to a multimedia support platform designed to provide rapid download of media elements needed to develop your story about HeartSciences and MyoVista Technology.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Hospital in Cox’s Bazar Will Offer 24/7 Medical Aid to 140,000 Rohingya Refugees14.11.2018 15:53 | Pressemelding
A 100-bed capacity hospital opened in Cox’s Bazar district in Bangladesh. It is expected to serve 140,000 Rohingya refugees based in the Kutupalong camp. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005631/en/ Sheikh Sultan bin Ahmed Al Qasimi, humanitarian envoy of the foundation and chairman of SMC inaugurated the hospital last Friday. (Photo: Business Wire) This round-the-clock medical facility, built and managed by Médecins Sans Frontières (MSF) – Doctors without Borders with the support of Sharjah-based international humanitarian organisation, The Big Heart Foundation (TBHF), aims to treat 7,200 people in its first year. Part of TBHF’s leading humanitarian efforts to reach out globally to vulnerable communities, this hospital project was supported by AED 3 million donation from Sharjah Media Corporation (SMC), through its public fundraising initiative on healthcare projects, and will offer much-needed relief to
Janssen Seeks Expanded Use of IMBRUVICA®▼ (ibrutinib) in Two Indications in Europe14.11.2018 14:23 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two Type II variation applications to the European Medicines Agency (EMA) seeking approval for the expanded use of IMBRUVICA® (ibrutinib). One application seeks to include use of ibrutinib in combination with obinutuzumab in previously untreated adults with chronic lymphocytic leukaemia (CLL) and to add long-term follow-up data from the existing label studies RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115). The second is for use of ibrutinib plus rituximab for the treatment of previously untreated and relapsed/refractory adults with Waldenström's macroglobulinemia (WM). “Today’s news brings us one step closer to potentially offering ibrutinib in new combinations for patients where unmet needs still persist,” said Dr. Catherine Taylor, Haematology Therapy Area Lead, Europe, Middle East and Africa (EMEA), Janssen-Cilag Limited. “Ibrutinib continues to demonstrate clinical benefit over the long
ResMed Completes Acquisition of MatrixCare14.11.2018 14:05 | Pressemelding
ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has completed its $750 million acquisition of Minnesota-based MatrixCare, a leader in software solutions for more than 15,000 providers across skilled nursing, life plan communities, senior living and private duty. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005282/en/ These care settings are complementary to ResMed’s other SaaS offerings in home medical equipment, home health and hospice, delivered through Brightree and HEALTHCAREfirst, acquired by ResMed in April 2016 and July 2018, respectively. ResMed will drive an integrated ecosystem of solutions across these platforms to maintain single-patient records across multiple care settings, generate analytics and insights that can be applied to individuals and whole populations, and streamline processes acr
REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 201814.11.2018 13:30 | Pressemelding
Today, the Board of Directors of Reply [MTA, STAR: REY] approved the results as at 30 September 2018. In the first nine months of the year, the Group has recorded a consolidated turnover of €754.4 million, with an increase of 15.8% compared to €651.3 million at September 2017. Consolidated EBITDA to September was €101.2 million (€89.8 million at September 2017) with an EBIT of €91.4 million (€81.7 million at September 2017). Pre-tax profit amounted to €96.3 million, which represents an increase of 22.4% compared to the same period of 2017. For the third quarter of 2018 (July-September), the Group registered a consolidated turnover of €256.3 million (€209.7 million in 2017), an EBITDA of €32.9 million (€28.0 million in 2017), an EBIT of €29.3 million (€24.7 million in 2017) and a pre-tax profit of €32.1 million (25.3 million in 2017). As at 30 September 2018, the Group's net financial position was positive for €56.3 million, improving compared to €50.2 million registered on June 30, 201
Blackjack Booster Lands at Intertops Poker14.11.2018 13:20 | Pressemelding
Intertops Poker is boosting player winnings this weekend with an extra 10% on the Lucktap games Blackjack, Face Up 21, Double Draw Blackjack and Perfect Pairs Blackjack. The promotion is being offered exclusively through the Intertops Poker software, and will run from Friday 16th November to Sunday 18th November. To access the promotion, players log into the Intertops Poker software and click the Casino tab in the top right hand corner. They then chose from one of the Lucktap games (Blackjack, Face Up 21, Double Draw Blackjack and Perfect Pairs Blackjack) offered and any winning bets will be increased by 10%. The additional 10% winnings will be shown as a bonus balance and will be released once the x15 wagering requirement has been met. The maximum prize that can be won is $250. The poker manager at Intertops Poker, said: “Here at Intertops Poker we are always looking to provide our players with even more value, which is why we are boosting all winnings on our Lucktap games by 10% this
Corsearch Announces Acquisition of Yellow Brand Protection14.11.2018 13:00 | Pressemelding
Corsearch Inc. and its related entities, a trademark and domain solutions leader, is pleased to announce the acquisition of Yellow Brand Protection AB of Sweden, a leading global provider of online anti-counterfeiting and brand protection services. The acquisition, effective immediately, solidifies and further expands Corsearch’s full service brand protection offering for clients and brands globally . The facts speak for themselves in this industry – In 2018, online sales will approach $3 trillion U.S. Dollars, with one in four online purchases involving pirated goods. Online IP infringement is a continued and increasingly expanding challenge for all brands, as e-commerce growth continues at record speed and digital marketing becomes a core business strategy. Corsearch, founded in 1949, provides industry-leading brand establishment and protection services for trademark and brand professionals in over 60 countries on five continents. Yellow Brand Protection, founded in 2010, provides br